Fulcrum Therapeutics, Inc.
FULC
Positions held
Your positionsFULC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $286.11M | Enterprise value | -$27.45M | Trailing P/E | — | Forward P/E | -6.85 |
| PEG | — | Price / book | 0.92 | Beta | 2.63 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -32.4% | ROA | -19.6% | Debt / equity | 0.02 |
| Current ratio | 31.35 | Free cash flow | -$37.37M | Analyst recommendation | none | Mean target | $3.67 |
| 52w high | $15.74 | 52w low | $2.83 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$26.2M | -$18.9M | -$20.3M | -$19.6M | -$17.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$19.9M | -$22.2M | -$22.7M | -$21.9M | -$19.8M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $80.0M | $2.8M | $6.3M |
| Op margin | — | -24.8% | -3945.2% | -1768.1% |
| Net income | -$74.9M | -$9.7M | -$97.3M | -$110M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$84.8M | -$19.8M | -$111M | -$112M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-27 · Slate Medicines Starts Migraine Treatment Study
2026-08-25 · Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
2026-08-18 · Fulcrum and Slate Medicines sign merger agreement
2026-08-18 · Fulcrum and Slate Medicines sign merger agreement
2026-08-17 · Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
2026-08-17 · Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
2026-08-17 · Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger
2026-08-17 · Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
2026-08-17 · Slate, Fulcrum to combine in reverse merger
2026-08-05 · Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
Price (daily)
Full chart · RSI · MACD · patterns